Published Date: 24 Dec 2024
One warns of "dangerous game" in continuing Medicare pay cuts
Read Full NewsA phase 2 study at CTAD 2025 explores VHB937's potential in treating early Alzheimer disease, focusing on safety and efficacy in patients.
In an analysis of the phase 2a CLEAR MIND study presented at CTAD 2025, laromestrocel treatment was associated with reduced hippocampal neuroinflammation in patients with mild Alzheimer disease.
A new phase 3 clinical trial is underway to evaluate masupirdine, a selective 5-HT6 receptor antagonist, as a potential treatment for agitation in patients with Alzheimer’s disease.
Pulmonary Rehabilitation Reduces Type 2 Inflammation in High Inflammation Asthma
Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention
6 Ophthalmology Headlines You Missed in October 2025
1.
Study confirms link between breast density, higher breast cancer risk
2.
The Predictive Power of Liquid Biopsy in Colon Cancer Outcomes Is Inconsistent.
3.
By acquiring T3 Pharma, a leader in bacterial cancer treatment, Boehringer Ingelheim broadens its offering in immunooncology.
4.
Is global cancer care losing its human touch?
5.
Researchers achieve a significant milestone in the management of anemia in chronic lymphocytic leukemia.
1.
Next-Gen Cancer Therapies: Radiopharmaceuticals, Immuno-Oncology, and Biologic Breakthroughs
2.
Unraveling the Genetic Mystery of Hereditary Spherocytosis
3.
AI Revolutionizes Immunotherapy: Unveiling Biomarkers with Machine Intelligence
4.
Exploring the Mysteries of MGUS: Uncovering the Causes and Treatments
5.
Seeing the Unseen: Examining Chancroid Through Images
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion
2.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
3.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II
4.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
5.
Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation